AZD2693
| Clinical data | |
|---|---|
| Other names | ION839 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
AZD2693 is an antisense therapy developed by AstraZeneca for the treatment of non-alcoholic fatty liver disease based on the PNPLA3 gene, believed to be the largest single genetic risk factor for this condition.[1][2][3][4]
References[edit]
- ^ Dolgin, Elie (1 May 2023). "NASH therapies head toward landmark approval". Nature Biotechnology. 41 (5): 587–590. doi:10.1038/s41587-023-01787-8. ISSN 1546-1696.
- ^ Cherubini, Alessandro; Casirati, Elia; Tomasi, Melissa; Valenti, Luca (2 December 2021). "PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date". Expert Opinion on Therapeutic Targets. 25 (12): 1033–1043. doi:10.1080/14728222.2021.2018418. hdl:2434/889573.
- ^ Sasso, Janet M.; Ambrose, Barbara J. B.; Tenchov, Rumiana; Datta, Ruchira S.; Basel, Matthew T.; DeLong, Robert K.; Zhou, Qiongqiong Angela (26 May 2022). "The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments". Journal of Medicinal Chemistry. 65 (10): 6975–7015. doi:10.1021/acs.jmedchem.2c00024. PMC 9115888.
- ^ Pirola, Carlos J.; Sookoian, Silvia (November 2021). "PNPLA3 and COVID‐19 outcomes: Thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system". Liver International. 41 (11): 2801–2804. doi:10.1111/liv.15043. ISSN 1478-3223. PMC 8662082.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |